NEWS
PRINCESS ANNE
OPENS BRANDON
MEDICAL’S NEW
FACILITY
SWITCHSTANCE SHOWCASES
GROUNDBREAKING CLAHRC RESEARCH
Healthcare software specialist, Switchstance has developed a
partnership with the East of England Collaboration for Leadership
in Applied Health Research and Care (CLAHRC EoE), to showcase
the work of the CLAHRC and how it improves patient care.
CLAHRC EoE’s undertakes world-class
applied health research, focused on
the needs of patients and support the
translation of research evidence into
practice in the NHS.
Following a highly successful first phase,
the CLAHRC programme has received
funding for a further five years of worldclass research. The partnership between
Switchstance and the CLAHRC addressed
a need to record, measure and monitor
the improvement of patient outcomes
through applied health research, by the
implementation of an online KPI system.
Switchstance is currently extending
the KPI system further and have also
created a web portal to link together the
CLAHRC’s key collaboration tools and
web presence.
Boost your business with
funded digital support
Switchstance is now an accredited
provider of strategic digital advice
through the Growth Voucher programme
backed by the Government.
The Government launched the £30
million programme to give small firms
subsidised expert support.
To find out how you can get involved,
visit the Switchstance website:
www.switchstanceit.com
L @SwitchstanceIT
CHINA BOOSTS RD BIOMED’S
GLOBAL GROWTH
RD Biomed has announced
a Chinese distribution
agreement for its reflux
diagnostic tool Peptest.
The deal with Hong Kong-based
investment and trading company MAAB
International will see Peptest launched
in China by 2016.
Peptest is the world’s first non-invasive
diagnostic test for all forms of reflux
disease. It measures the presence of
the digestive enzyme pepsin in a clinical
sample, such as saliva, which is a
reliable marker for the reflux of gastric
juice. Research has shown
reflux is increasing in prevalence in
China, with approximately 120 million
adults suffering from heartburn and
reflux symptoms.
Under the exclusive three-year
distribution agreement, MAAB
International will be responsible for
registering Peptest with Chinese
regulatory body the China Food and Drug
Administration (CFDA), with an official
launch estimated in 2016 once licencing
has been finalised. Through its partners
in China, MAAB International has access
to a nationwide network of sales and
distribution channels.
For more information about RD Biomed
visit: www.rdbiomed.com
L @peptest_reflux
HRH the Princess Royal
recently visited Medilink
member Brandon Medical.
The visit of Princess Anne was to mark
the official opening of a new facility
that will double the operating capacity
at Brandon Medical.
The Princess was also invited to
Brandon’s state of the art visitor
centre to test an impressive portfolio
of products. This was followed by a
tour of the factory before the final
grand plaque unveiling.
The innovative centre features a
demonstration operating theatre,
ICU and GP Surgery. These additions
will see the company showcase its
OT lighting, examination lighting and
medical architectural systems in a
more realistic setting.
Brandon Medical’s focus is to
consolidate the design, production and
sales of its medical equipment into one
location, which will create more jobs in
the local area.
Graeme Hall, Managing Director of
Brandon Medical said: “It was a joy to
welcome Princess Anne to Brandon
Medical. We enjoyed the opportunity
to demonstrate how our technologies
are improving the everyday lives of
healthcare professionals across the
globe and how our achievements
have allowed us to relocate to such a
fantastic new facility.”
For more information on Brandon
Medical visit:
ww.brandon-medical.com
L @BrandonMedical
07